Oramed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2006
Cash & Equivalents	9.06	40.46	77.25	19.3	3.33	5	3.99	3.92	3.23	1.78	Upgrade
Short-Term Investments	152.99	115.26	16.9	20.6	28.95	25.47	16.15	27.11	14.02	19.53	Upgrade
Cash & Cash Equivalents	162.05	155.72	94.14	39.9	32.28	30.46	20.14	31.03	17.25	21.31	Upgrade
Cash Growth	4.06%	65.41%	135.94%	23.60%	5.97%	51.27%	-35.11%	79.95%	-19.06%	150.92%	Upgrade
Receivables	0	0	0	0	0	0	0	0	0	0.08	Upgrade
Other Current Assets	0.54	1.39	1.2	0.61	1.04	0.57	0.16	0.2	0.13	0.39	Upgrade
Total Current Assets	162.58	157.11	95.34	40.51	33.32	31.04	20.3	31.23	17.37	21.78	Upgrade
Property, Plant & Equipment	1.57	1.8	0.93	0.17	0.02	0.02	0.02	0.02	0.01	0.01	Upgrade
Long-Term Investments	56.37	2.71	31.71	3.93	1.3	16.33	18.38	11.57	8.96	0	Upgrade
Other Long-Term Assets	0.03	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	Upgrade
Total Long-Term Assets	57.97	4.53	32.66	4.12	1.34	16.36	18.42	11.6	8.98	0.02	Upgrade
Total Assets	220.55	161.64	128	44.63	34.66	47.4	38.71	42.83	26.35	21.8	Upgrade
Accounts Payable	1.61	4.16	3.85	1.7	2.54	2.06	2.72	1.41	0.95	0.93	Upgrade
Deferred Revenue	4	5.34	6.95	9.65	12.36	13.84	16.29	14.77	0.5	0	Upgrade
Current Debt	51.28	0.25	0.13	0.04	0	0	0	0	0	0	Upgrade
Other Current Liabilities	-3.68	-4	-4.24	-6.86	-9.59	-11.34	-13.84	-12.56	0.04	0.05	Upgrade
Total Current Liabilities	53.21	5.75	6.68	4.54	5.31	4.55	5.17	3.62	1.49	0.97	Upgrade
Long-Term Debt	0.34	0.65	0.4	0.03	0	0	0	0	0	0	Upgrade
Other Long-Term Liabilities	4.1	4.09	4.4	7.19	9.96	11.73	14.31	13.02	0.04	0.04	Upgrade
Total Long-Term Liabilities	4.44	4.74	4.8	7.22	9.96	11.73	14.31	13.02	0.04	0.04	Upgrade
Total Liabilities	57.66	10.49	11.48	11.75	15.27	16.29	19.47	16.64	1.53	1.01	Upgrade
Total Debt	51.62	0.89	0.53	0.08	0	0	0	0	0	0	Upgrade
Debt Growth	5674.27%	67.73%	610.67%	-	-	-	-	-	-	-	Upgrade
Retained Earnings	-157.56	-163.08	-114.85	-92.61	-81.1	-69.22	-56.5	-46.02	-35.05	-27.82	Upgrade
Comprehensive Income	0	0	0	0	0	0.7	0.4	0.11	0.56	0.45	Upgrade
Shareholders' Equity	163.82	151.81	115.77	32.88	19.39	31.11	19.24	26.19	24.83	20.79	Upgrade
Net Cash / Debt	110.43	154.83	93.61	39.83	32.28	30.46	20.14	31.03	17.25	21.31	Upgrade
Net Cash / Debt Growth	-28.68%	65.40%	135.05%	23.37%	5.97%	51.27%	-35.11%	79.95%	-19.06%	150.92%	Upgrade
Net Cash Per Share	2.72	3.97	3.29	1.94	1.85	2.05	1.51	2.46	1.59	2.30	Upgrade
Working Capital	109.37	151.36	88.66	35.98	28.02	26.48	15.13	27.61	15.88	20.81	Upgrade
Book Value Per Share	4.06	3.89	4.07	1.60	1.11	2.09	1.45	2.08	2.29	2.25	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).